YXYusang Xie

Yusang Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yusang Xie has a total of 76 co-authors. Here are the top co-authors by number of shared publications:

  • Jieming Qu

    Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    4 shared publications
  • Min Zhou

    Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine

    4 shared publications
  • Bei He

    Department of Pulmonary and Critical Care Medicine, Peking University Third Hospital, Beijing, China

    2 shared publications
  • Danyang She

    Department of Pulmonary and Critical Care Medicine, The General Hospital of the People's Liberation Army, Beijing, China

    2 shared publications
  • Dongwei Shi

    Department of Emergency Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

    2 shared publications
  • Feng Ye

    Department of Pulmonary and Critical Care Medicine, The First Affiliate Hospital of Guangzhou Medical University, Guangzhou, China

    2 shared publications

Latest Publications

  • Open Access

    ALCAM is an entry factor for severe community acquired Pneumonia-associated Human adenovirus species B

    by Yusang Xie, Hong Mei, Wei Wang, Xiao Li, Pengfei Hu, Xingui Tian, Rong Zhou, Jia Liu, Jieming Qu

    Human adenovirus (HAdV) is a widely spread respiratory pathogen that can cause infections in multiple tissues and organs. Previous studies have established an association between HAdV species B (HAdV-B) infection and severe community-acquired pneumonia (SCAP). However, the connection between SCAP-associated HAdV-B infection and host factor expression profile in patients has not been systematically investigated. Here, we perform a CRISPR genetic screen on HAdV-B using two generations of cell surface protein-focused CRISPR libraries and identify a series of host factors including the known receptor DSG-2 and an unknown factor, activated leukocyte cell adhesion molecule (ALCAM). Further investigation shows that ALCAM affects HAdV-B infection by participating in viral internalization. Transcriptomics data from human blood samples suggests that ALCAM expression is higher in SCAP patients with HAdV-B infection than in those with other infections. Chimeric and authentic virus experiments show that ALCAM is a widely used host factor across B1 and B2 genetic clusters of HAdV-B. The dissociation constant between the knob domain of HAdV-B fiber and ALCAM is 837 nM in average. In summary, our results suggest that ALCAM is an entry factor for SCAP-associated HAdV-B.


  • Open Access

    Liver dysfunction on admission worsens clinical manifestations and outcomes of coronavirus disease 2019

    by Fangying Lu, Rong Chen, Kandi Xu, Jie Huang, Dexiang Yang, Tao Bai, Yusang Xie, Yun Ling, Kui Liu, Wei Du, et al.


  • Open Access

    A multicenter prospective study of comprehensive metagenomic and transcriptomic signatures for predicting outcomes of patients with severe community-acquired pneumonia

    by Jingya Zhao, Xiangyan He, Jiumeng Min, Rosary Sin Yu Yao, Yu Chen, Zhonglin Chen, Yi Huang, Zhongyi Zhu, Yanping Gong, Yusang Xie, et al.


  • Top Cited Papers
    Open Access

    Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China

    by Jieming Qu, Jing Zhang, Yu Chen, Yi Huang, Yusang Xie, Min Zhou, Yuping Li, Dongwei Shi, Jinfu Xu, Qiuyue Wang, et al.

    Severe Community Acquired Pneumonia (SCAP) challenges public health globally. Considerable improvements in molecular pathogen testing emerged in the last few years. Our prospective study combinedly used traditional culture, antigen tests, PCR and mNGS in SCAP pathogen identification with clinical outcomes. From June 2018 to December 2019, we conducted a multi-centre prospective study in 17 hospitals of SCAP patients within 48 hours of emergency room stay or hospitalization in China. All clinical data were uploaded into an online database. Blood, urine and respiratory specimens were collected for routine culture, antigen detection, PCR and mNGS as designed appropriately. Aetiology confirmation was made by the local attending physician group and scientific committee according to microbiological results, clinical features, and response to the treatment. Two hundred seventy-five patients were included for final analysis. Combined detection methods made identification rate up to 74.2% (222/299), while 14.4% (43/299) when only using routine cultures and 40.8% (122/299) when not using mNGS. Influenza virus (23.2%, 46/198), S. pneumoniae (19.6%, 39/198), Enterobacteriaceae (14.6%, 29/198), Legionella pneumophila (12.6%, 25/198), Mycoplasma pneumoniae (11.1%, 22/198) were the top five common pathogens. The in-hospital mortality of patients with pathogen identified and unidentified was 21.7% (43/198) and 25.9% (20/77), respectively. In conclusion, early combined detection increased the pathogen identification rate and possibly benefitted survival. Influenza virus, S. pneumoniae, Enterobacteriaceae was the leading cause of SCAP in China, and there was a clear seasonal distribution pattern of influenza viruses. Physicians should be aware of the emergence of uncommon pathogens, including Chlamydia Psittaci and Leptospira.


  • Open Access

    The mNCP-SPI Score Predicting Risk of Severe COVID-19 among Mild-Pneumonia Patients on Admission

    by Lingxi Guo, Weining Xiong, Dong Liu, Yun Feng, Peng Wang, Xuan Dong, Rong Chen, Yi Wang, Lei Zhang, Jingwen Huang, et al.

    Purpose: To predict the risk of developing severe pneumonia among mild novel coronavirus pneumonia (mNCP) patients on admission. Methods: A retrospective cohort study was conducted at three hospitals in Shanghai and Wuhan from January 2020 to February 2020. Real-time polymerasechain–reaction assays were used to detect COVID-19. A total of 529 patients diagnosed with NCP were recruited from three hospitals and classified by four severity types during hospitalization following the standards of the Chinese Diagnosis and Treatment of Pneumonia Caused by New Coronavirus Infection (eighth version). Patients were excluded if admitted by ICU on admission (n=92, on a general ward while meeting the condition of severe or critical type on admission (n=25), or there was insufficient clinical information (n=64). In sum, 348 patients with mNCP were finally included, and 68 developed severe pneumonia. Results: mNCP severity prognostic index values were calculated based on multivariate logistic regression: history of diabetes (OR 2.064, 95% CI 1.010– 4.683; p=0.043), time from symptom onset to admission ≥ 7 days (OR 1.945, 95% CI 1.054– 3.587; p=0.033), lymphocyte count ≤ 0.8 (OR 1.816, 95% CI 1.008– 3.274; p=0.047), myoglobin ≥ 90 mg/L (OR 2.496, 95% CI 1.235– 5.047; p=0.011), and D-dimer ≥ 0.5 mg/L (OR 2.740, 95% CI 1.395– 5.380; p=0.003). This model showed a c-statistics of 0.747, with sensitivity and specificity 0.764 and 0.644, respectively, under cutoff of 165. Conclusion: We designed a clinical predictive tool for risk of severe pneumonia among mNCP patients to provided guidance for medicines. Further studies are required for external validation.